Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Sanofi's Sarclisa Escena (isatuximab) wins FDA approval as first on-body injector anticancer drug for multiple myeloma
Antibody, cancer, monoclonal antibody, multiple myeloma, CD38, subcutaneous delivery - Read more

Conba Pharmaceutical secures exclusive rights to Adneuris Therapeutics' cebranopadol in Greater China, $111.5M deal
Licensing deal, small molecule, pain management, milestone payments, commercialization - Read more

Rani Therapeutics, PegBio collaborate on oral delivery of multiple obesity and metabolic disease pipeline candidates
Research collaboration, obesity, drug delivery, biologics, oral delivery - Read more

Simcere Pharmaceutical, Schrödinger collaborate on global drug discovery using computational platform, milestones and tiered royalties included
Research collaboration, drug discovery, AI/ML, small molecule, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) Ph3 trial meets overall survival endpoint in small cell lung cancer
Antibody-drug conjugate, cancer, small cell lung cancer, B7-H3 target, chemotherapy combination - Read more

Forte Biosciences' FB102 (FB102) shows 45.8% placebo-adjusted benefit in vitiligo in Ph1b trial
Antibody, autoimmune, monoclonal antibody, vitiligo, CD122 target, IL-15 pathway - Read more

Mesoblast Limited reports Ryoncil fourth-quarter net revenue of $36M, full-year $115M
Cell therapy, rare disease, revenue impact, financial - Read more

Cue Biopharma raises $50M private placement, funding clinical development of immunological disorder therapies
Clinical-stage, immunology, biopharmaceutical, autoimmune - Read more

AstraZeneca wins US appeals court ruling, confirming Tagrisso doesn't infringe Pfizer's Wyeth patents
Small molecule, oncology, competitive, revenue impact - Read more

Sobi tops bleeding disorder pharma reputation rankings in PatientView's 2025/2026 annual survey
Bleeding disorder, rare disease, competitive, patient advocacy - Read more

McKinsey report calls for biopharma R&D "structural redesign" to maximize AI's compounding learning potential
AI drug discovery, multiple disease areas, operational, strategic - Read more

ARPA-H awards up to $160M to teams developing personalized genetic medicines for rare diseases
Rare disease, gene therapy, personalized medicine, platform technology, pediatric - Read more

Sobi wins positive Canadian reimbursement recommendation for EMPAVELI® in rare kidney diseases C3G and IC-MPGN
Small molecule, rare disease, regulatory, reimbursement - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Bausch + Lomb pivots BL1107 to geographic atrophy sustained-release implant after Ph2 glaucoma miss
Small molecule, ophthalmology, geographic atrophy, glaucoma, sustained-release implant - Read more

Roche discontinues (tominersen) and RG6496 for Huntington's disease after Ph2 efficacy failure and Ph1 safety concerns
Antisense oligonucleotide, neurological, Huntington's disease, huntingtin protein, small molecule - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here